Mäneka Puligandla

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial”.

Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial

Blood Advances(2020)10.1182/bloodadvances.2020001804

N/A

0.920DataRank · unranked

30 citations

Joanna Roopkumar, Mäneka Puligandla, Benjamin L. Schlechter, Anish V. Sharda, David M. Peereboom +6 more

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

Cancer Medicine(2021)10.1002/cam4.4140

N/A

0.315DataRank · unranked

5 citations

Hannah Fullington, David E. Gerber, I. Alex Bowman, Mäneka Puligandla, Janice P. Dutcher +3 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0025

N/A

0DataRank · unranked

46 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo +5 more

Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries

Blood Advances(2021)10.1182/bloodadvances.2021004347

N/A

0DataRank · unranked

20 citations

Oscar Silva, Elizabeth Solórzano-Ortiz, Mäneka Puligandla, Marcos Mauricio Siliézar Tala, Timothy Guyon +10 more

ORAL MERCAPTOPURINE ADHERENCE IN PEDIATRIC ALL: A SURVEY STUDY FROM THE DFCI ALL CONSORTIUM

(2020)10.22541/au.160322421.10925954/v1

N/A

0DataRank · unranked

0 citations

Mäneka Puligandla, Kristen E. Stevenson, Peter D. Cole, Jennifer Welch, Melissa Beauchemin +5 more

Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.342

N/A

0DataRank · unranked

0 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert Guy Uzzo +5 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more